Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis.

被引：0
|
作者：
Jani, Meghna [1 ]
Chinoy, Hector [1 ]
Warren, Richard B. [2 ]
Griffiths, Christopher E. M. [2 ]
Morgan, Ann W. [3 ]
Wilson, Anthony G. [4 ]
Hyrich, Kimme L. [1 ]
Isaacs, John [5 ]
Plant, Darren [1 ]
Barton, Anne [6 ]
机构：
[1] Univ Manchester, Ctr Musculoskeletal Res, Manchester 2, Lancs, England
[2] Univ Manchester, Dermatol Ctr, Manchester, Lancs, England
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Univ Coll Dublin, Dublin, Ireland
[5] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England
[6] Manchester Acad Hlth Sci Ctr, NIHR Manchester Musculoskeletal Biomed Res Unit, Manchester, Lancs, England
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2924
引用
收藏
页码：S1278 / S1278
页数：1
相关论文
共 50 条
  • [31] ANTINUCLEAR ANTIBODIES IN RHEUMATOID ARTHRITIS: PREDICTORS OF RESPONSE TO ANTI-TNF ALPHA TREATMENT?
    Fonseca, R.
    Vieira, R.
    Madureira, P.
    Rosa-Goncalves, D.
    Aguiar, F.
    Rocha, T.
    Bernardo, A.
    Mariz, E.
    Bernardes, M.
    Costa, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1293 - 1293
  • [32] Anti-TNF and Anti-Drug Antibodies Levels Predict the Outcomes of Interventions After Loss of Response to Adalimumab and Infliximab
    Yanai, Henit
    Lichtenstein, Lev
    Assa, Amit
    Mazor, Yoav
    Weiss, Batia
    Levine, Arie
    Ron, Yulia
    Kopylov, Uri
    Bujanover, Yoram
    Rosenbach, Yoram
    Ungar, Bella
    Eliakim, Abraham R.
    Chowers, Yehuda
    Shamir, Raanan
    Fraser, Gerald
    Dotan, Iris
    Ben-Horin, Shomron
    GASTROENTEROLOGY, 2014, 146 (05) : S381 - S381
  • [33] Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug A Randomized Clinical Trial
    Gottenberg, Jacques-Eric
    Brocq, Olivier
    Perdriger, Aleth
    Lassoued, Slim
    Berthelot, Jean-Marie
    Wendling, Daniel
    Euller-Ziegler, Liana
    Soubrier, Martin
    Richez, Christophe
    Fautrel, Bruno
    Constantin, Arnaud L.
    Mariette, Xavier
    Morel, Jacques
    Gilson, Melanie
    Cormier, Gregoire
    Salmon, Jean Hugues
    Rist, Stephanie
    Liote, Frederic
    Marotte, Hubert
    Bonnet, Christine
    Marcelli, Christian
    Sellam, Jeremie
    Meyer, Olivier
    Solau-Gervais, Elisabeth
    Guis, Sandrine
    Ziza, Jean-Marc
    Zarnitsky, Charles
    Chary-Valckenaere, Isabelle
    Vittecoq, Olivier
    Saraux, Alain
    Pers, Yves-Marie
    Gayraud, Martine
    Bolla, Gilles
    Claudepierre, Pascal
    Ardizzone, Marc
    Dernis, Emmanuelle
    Breban, Maxime A.
    Fain, Olivier
    Balblanc, Jean-Charles
    Aberkane, Ouafaa
    Vazel, Marion
    Back, Christelle
    Candon, Sophie
    Chatenoud, Lucienne
    Perrodeau, Elodie
    Sibilia, Jean
    Ravaud, Philippe
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (11): : 1172 - 1180
  • [34] Characterization of Neutralizing Anti-Drug Antibody Response in Patients With Loss of Response to Anti-TNF Therapy
    Hauenstein, Scott
    Salbato, Jared
    Lockton, Steven
    Singh, Sharat
    GASTROENTEROLOGY, 2013, 144 (05) : S418 - S418
  • [35] Immunogenicity, the elephant in the room. Comment on “Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases”
    John Pixley
    Clinical Rheumatology, 2013, 32 : 1413 - 1413
  • [36] Immunogenicity, the elephant in the room. Comment on "Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases"
    Pixley, John
    CLINICAL RHEUMATOLOGY, 2013, 32 (10) : 1413 - 1413
  • [37] Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis
    Tanaka, Yoshiya
    Miyazaki, Yusuke
    Kawanishi, Masafumi
    Yamasaki, Hironori
    Takeuchi, Tsutomu
    RMD OPEN, 2024, 10 (03):
  • [38] The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug
    Soderlin, M. K.
    Petersson, I. F.
    Geborek, P.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2012, 41 (01) : 1 - 9
  • [39] Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab
    Nicholas J. Costable
    Zachary A. Borman
    Jiayi Ji
    Marla C. Dubinsky
    Ryan C. Ungaro
    Digestive Diseases and Sciences, 2022, 67 : 2480 - 2484
  • [40] Long-term effect of anti-TNF treatment on atherosclerosis risk factors in rheumatoid arthritis patients
    Sayo, Yoshitaka
    Dobashi, Hiroaki
    Matsubara, Shur
    Tada, Satoshi
    Taminato, Tomohiko
    Ishiija, Toshihiko
    DIABETES, 2008, 57 : A601 - A601
12345